| Title |
Early Ketamine to Treat Refractory Status Epilepticus
|
|---|---|
| Published in |
Neurocritical Care, January 2012
|
| DOI | 10.1007/s12028-011-9668-7 |
| Pubmed ID | |
| Authors |
Andreas H. Kramer |
| Abstract |
Management of refractory status epilepticus (SE) involves administration of intravenous γ-aminobutyric acid (GABA(A)) receptor agonists, such as benzodiazepines, barbiturates, or propofol. Animal models suggest that reductions in synaptic GABA(A) receptors may cause these drugs to become less effective as the duration of SE increases. This may explain the large doses that are commonly required to control seizures, which in turn contributes to a high incidence of complications, including hypotension and the need for vasopressors. In contrast, expression of excitatory N-methyl-D-aspartate (NMDA) receptors increases with prolonged SE and their stimulation by glutamate may propagate seizure activity. Ketamine is a NMDA-receptor antagonist that is considered promising as treatment for refractory SE. Compared with other anaesthetic drugs, ketamine produces less hypotension. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 75% |
| Australia | 1 | 25% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 75% |
| Practitioners (doctors, other healthcare professionals) | 1 | 25% |
Mendeley readers
The data shown below were compiled from readership statistics for 102 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 3 | 3% |
| United States | 2 | 2% |
| Switzerland | 1 | <1% |
| Spain | 1 | <1% |
| Belgium | 1 | <1% |
| Unknown | 94 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 21 | 21% |
| Other | 13 | 13% |
| Student > Postgraduate | 11 | 11% |
| Student > Ph. D. Student | 8 | 8% |
| Professor | 7 | 7% |
| Other | 25 | 25% |
| Unknown | 17 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 57 | 56% |
| Agricultural and Biological Sciences | 6 | 6% |
| Neuroscience | 4 | 4% |
| Nursing and Health Professions | 3 | 3% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Other | 9 | 9% |
| Unknown | 20 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 January 2016.
All research outputs
#2,944,824
of 23,577,654 outputs
Outputs from Neurocritical Care
#254
of 1,548 outputs
Outputs of similar age
#23,722
of 247,108 outputs
Outputs of similar age from Neurocritical Care
#2
of 7 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. Compared to these this one has done well and is in the 87th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,548 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 247,108 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.